{
    "clinical_study": {
        "@rank": "149823", 
        "arm_group": [
            {
                "arm_group_label": "OPC-1085EL ophthalmic solution", 
                "arm_group_type": "Experimental", 
                "description": "Once daily"
            }, 
            {
                "arm_group_label": "Carteolol long-acting ophthalmic solution", 
                "arm_group_type": "Active Comparator", 
                "description": "Once daily"
            }, 
            {
                "arm_group_label": "Latanoprost ophthalmic solution", 
                "arm_group_type": "Active Comparator", 
                "description": "Once daily"
            }
        ], 
        "brief_summary": {
            "textblock": "OPC-1085EL ophthalmic solution, carteolol long-acting ophthalmic solution or latanoprost\n      ophthalmic solution are administered once daily for 7 days and the effect on the blood\n      concentration of carteolol and latanoprost in OPC-1085EL ophthalmic solution by formulating\n      the combination drug will be determined."
        }, 
        "brief_title": "Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Glaucoma", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who are considered medically healthy per investigator's judgment\n\n        Exclusion Criteria:\n\n          -  Subjects with ocular conditions as defined by the protocol\n\n          -  Subjects with intraocular pressure: <10 or \u226522 mmHg"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02108288", 
            "org_study_id": "1085EL-13-004"
        }, 
        "intervention": [
            {
                "arm_group_label": "OPC-1085EL ophthalmic solution", 
                "intervention_name": "OPC-1085EL ophthalmic solution", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Carteolol long-acting ophthalmic solution", 
                "intervention_name": "Carteolol long-acting ophthalmic solution", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Latanoprost ophthalmic solution", 
                "intervention_name": "Latanoprost ophthalmic solution", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carteolol", 
                "Latanoprost"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kansai Region", 
                    "country": "Japan"
                }
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "overall_contact": {
            "last_name": "Drug Information Center", 
            "phone": "+81-3-6361-7314"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Plasma concentration of carteolol and latanoprost acid", 
            "safety_issue": "No", 
            "time_frame": "Day 1 to Day 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02108288"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cmax of carteolol and latanoprost acid", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 7"
            }, 
            {
                "measure": "AUC of carteolol and latanoprost acid", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 7"
            }, 
            {
                "measure": "Tmax of carteolol and latanoprost acid", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 7"
            }, 
            {
                "measure": "\u03bbz of carteolol and latanoprost acid", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 7"
            }, 
            {
                "measure": "t1/2 of carteolol and latanoprost acid", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 7"
            }, 
            {
                "measure": "tlast of carteolol and latanoprost acid", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 7"
            }
        ], 
        "source": "Otsuka Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}